IDEAYA Biosciences, Inc.

NASDAQ:IDYA

Biotechnology

Healthcare
$26.49 -1.45%

-$0.45 today

Market cap
$2.56B
Beta
-0.05
P/E (TTM)
-19.5
EPS (TTM)
-$1.58
52W Low $20.50High $39.28

Volume 1.45M

Average 1.44M

IDYA Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

IDEAYA Biosciences, Inc.NASDAQ: IDYA

Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Investing cash flow grows, but more slowly than its trailing trend

Q1 FY2026 investing cash flow of $118.95M rose 49.0% year over year, behind the +258.7% change in trailing-twelve-month investing cash flow.

Context

  • Investing cash flow amounted to 32.0% of revenue in FY2025, down 7147.4 pp from a year earlier.
  • Investing cash flow increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +49.0% toward the trailing-twelve-month pace of +258.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$118.95M+222.0% QoQ
Last fiscal yearDec 2025
$69.98M+113.9% YoY
LTMMar 2026
$109.11M+258.7% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+49.0%——
1 year+113.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

USD · from the cash flow

Latest · FY2025
69.98M USD
Year-over-year change
+113.9%

Investing Cash Flow vs competitors

How IDYA compares with its peers on the latest reported figures

  • IDYA's LTM Mar 2026 investing cash flow of $109.11M is the 5th largest of the 9 companies compared; the peer median is $262.82M.
  • Its year-over-year change of +258.7% is the 2nd highest of 9, against a peer median of -144.3%.
  • Investing cash flow amounts to 48.4% of revenue for IDYA, versus a peer median of 26.5%.
IDYA Competitors Peer median
Investing Cash Flow for IDYA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RVMDRevolution Medicines, Inc.LTM Jun 2026$1.39B +250.0%——
TNGXTango Therapeutics, Inc.LTM Sep 2026$796.04M -641.8%——
ERASErasca, Inc.LTM Sep 2026$687.97M -799.6%——
COGTCogent Biosciences, Inc.LTM Jun 2026$499.99M -349.8%+47.4%—
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$109.11M +258.7%—48.4%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$64.92M +335.2%—230.0%
VSTMVerastem, Inc.LTM Mar 2026$25.64M -188.4%—51.7%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$1.1M -83.6%+75.8%0.2%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$228K -100.2%-13.2%1.4%
Peer median (excluding IDYA) $262.82M-144.3%+47.4%26.5%

Competitors are the stored peer set for IDYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(49.76M)(58.66M)(112.96M)(274.48M)(113.7M)
Depreciation & Amortization1.73M2.1M4.01M3.83M4.59M
Deferred Income Tax00000
Stock-Based Compensation8.24M11.63M18.49M34.75M46.12M
Change in Working Capital(17.81M)(41.56M)(13.21M)11.55M1.87M
Accounts Receivables774K892K193K15K0
Inventory3.79M0000
Accounts Payables1.17M1.86M2.64M8.28M2.7M
Other Working Capital(23.54M)(44.31M)(16.04M)3.25M(829K)
Other Non-Cash Items1.83M(695K)(11.55M)(23.23M)(9.98M)
Operating Cash Flow(55.78M)(87.18M)(115.22M)(247.58M)(71.1M)
Capital Expenditures(2.64M)(3.44M)(2.37M)(3.86M)(2.37M)
Acquisitions (Net)67.02M33.4M000
Purchases of Investments(315M)(255.81M)(595.98M)(1.19B)(607.89M)
Sales of Investments247.97M225.85M439.89M692.61M680.23M
Other Investing Activities(67.02M)(33.4M)000
Investing Cash Flow(69.67M)(33.4M)(158.46M)(502.56M)69.98M
Debt Repayment00000
Common Stock Issued143.25M94.96M309.76M654.23M29.78M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.2M2.2M10.77M13.92M0
Financing Cash Flow145.45M97.17M362.72M677.55M29.78M
Effect of Forex Changes0000(210K)
Net Change in Cash20.01M(23.41M)89.04M(72.59M)28.45M
Free Cash Flow(58.42M)(90.62M)(117.59M)(251.44M)(73.47M)

IDEAYA Biosciences, Inc.

NASDAQ:IDYA

Intrinsic Alpha fair value

Locked

Current Price

$26.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.